Pregnancy in Takayasu Arteritis Patients Exposed to Anti-Tumour Necrosis Factor (Anti-TNF)-α Therapy
Journal Title: Gynecology and Obstetrics Research – Open Journal - Year 2016, Vol 2, Issue 5
Abstract
Anti-TNF agents, IFX in particular,1 appear safe and effective in rheumatic patients during pregnancy. Here, we described two successful pregnancies of TA patients treated with IFX before conception and until 28 wg. Blood pressure remained optimal and the vascular inflammation/remodelling did not worsen.6 Newborns were healthy. We followed the indication to discontinue IFX during the last trimester6 : This approach seems to be safe for the mother and minimizes fetal exposition to the drug. The risk of infections is low. In our reported cases infections were not observed in postpartum period till one years follow-up of the babies. In infants exposed to infliximab in utero a normal antibody response to standard vaccinations is ensuring in the early childhood.7 Live vaccines are recommended after 6 months of age in infants exposed to anti-TNF in utero.8 To the best of our knowledge, this is the first report describing the use of anti-TNF agents in pregnant TA patients.
Authors and Affiliations
Valentina Canti
Keywords
Related Articles
- EP ID EP553588
- DOI 10.17140/GOROJ-2-122
- Views 189
- Downloads 0
Assessment of Maternal Nifedipine as a Tocolytic Agent on the Doppler Indices of Uterine and Fetal Umbilical and Middle Cerebral Arteries
Objective: This study was designed to assess the effects of maternal nifedipine administration on blood flow resistance in uterine, umbilical and fetal middle cerebral arteries by evaluating resistance index (RI) and pul...
Analyzing Pregnancy Costs with Finite Mixture Models: An Opportunity to More Adequately Accommodate the Presenceof Patient Data Heterogeneity
The choice of a model in the analysis of patient health care costs and utilization is critical for a clear understanding of the behavior and estimation of quantities like incremental costs or cost-effectiveness. In study...
The Use of Localised Vaginal Drug Delivery as Part of a Neoadjuvant Chemotherapy Strategy in the Treatment of Cervical Cancer
Cervical cancer is the third most prevalent cancer in women globally, with 529,000 diagnosis and 275,000 deaths each year. It is especially prevalent in developing countries where approximately 85% of cases arise due to...
Pregnancy and Childbirth in Patients With Syndrome-MarfanPregnancy and Childbirth in Patients With Syndrome-Marfan
Marfan syndrome (MFS) is an autosomal dominant condition with a reported incidence rate of 1 in 3000 to 5000 individuals. The majority of cases of MFS are caused by a mutation in the fibrillin-1 gene (FBN1). Transforming...
Human Placentas and the Changing Face of Reproductive Toxicology Testing
Pharmaceuticals are in use by 40-98% of pregnant mothers in the developed world, varying by country. There is a significant potential for obstetricians to further maintain medical prescriptions for chronic diseases durin...